Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease.

Little is known about the factors that predict clinical relapse in Crohn's disease patients receiving thiopurine therapy to maintain remission. The objective of this study was, therefore, to investigate these factors.
A total of 82 Crohn's disease patients who received their first course of azathioprine or 6-mercaptopurine treatment at Severance Hospital between June 1996 and July 2007 were recruited to the study. During the follow-up period (25.5 ± 16.6 months) 19 patients (23.2%) discontinued the medication because of significant adverse effects. Forty-five patients who continued to receive thiopurines to maintain medically or surgically induced remission were enrolled in the study. After adjusting the maintenance dose, patients in remission were followed at 2-3 month intervals. Relapse was defined as a Crohn's disease activity index ≥ 150.
The male-to-female ratio was 1.5:1 and the mean age was 26.3 ± 7.1 years. Cumulative relapse was 18.0% after one year and 49.2% after three years. According to multivariate Cox regression analysis, younger age (<30 years) at thiopurine therapy and increased C-reactive protein level (≥ 0.5 mg/dL) at remission were independent predictors of relapse (hazard ratio 19.751, 95%-confidence interval (CI) 1.996-195.402, P = 0.011 and hazard ratio 9.001, 95% CI 1.583-51.181, P = 0.013, respectively).
Younger age (<30 years) and increased C-reactive protein level at remission were independent predictors of relapse in Crohn's disease patients receiving thiopurines to maintain remission. These high-risk groups warrant closer observation and possibly early introduction of biological agents.
AuthorsJae Jun Park, Jae Hee Cheon, Sung Pil Hong, Tae Il Kim, Won Ho Kim
JournalDigestive diseases and sciences (Dig Dis Sci) Vol. 57 Issue 1 Pg. 133-41 (Jan 2012) ISSN: 1573-2568 [Electronic] United States
PMID22057283 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • Immunosuppressive Agents
  • C-Reactive Protein
  • 6-Mercaptopurine
  • Azathioprine
  • 6-Mercaptopurine (therapeutic use)
  • Adult
  • Age Factors
  • Azathioprine (therapeutic use)
  • Biomarkers (blood)
  • C-Reactive Protein (metabolism)
  • Crohn Disease (blood, diagnosis, drug therapy)
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Male
  • Predictive Value of Tests
  • Prognosis
  • Recurrence
  • Regression Analysis
  • Republic of Korea
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: